Sionna Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Public

  • Employees
  • 59

Employees

  • Stock Symbol
  • SION

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $2.97
  • (As of Thursday Closing)

Sionna Therapeutics General Information

Description

Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 21 Hickory Drive
  • Suite 500
  • Waltham, MA 02451
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 21 Hickory Drive
  • Suite 500
  • Waltham, MA 02451
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sionna Therapeutics Stock Performance

As of 19-Nov-2026, Sionna Therapeutics’s stock price is $2.97. Its current market cap is $134M with 45.2M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.97 $2.96 $2.89 - $54.97 $134M 45.2M 1.15M -$2.44

Sionna Therapeutics Financials Summary

As of 30-Sep-2026, Sionna Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 34,855 1,596,667
Revenue 0 0 0 0
EBITDA (119,894) (87,916) (69,190) (49,449)
Net Income (109,523) (75,268) (61,688) (47,263)
Total Assets 263,261 325,953 185,752 51,945
Total Debt 7,751 8,677 9,749 10,477
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Sionna Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sionna Therapeutics‘s full profile, request access.

Request a free trial

Sionna Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Sionna Therapeutics‘s full profile, request access.

Request a free trial

Sionna Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatmen
Drug Discovery
Waltham, MA
59 As of 2025

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sionna Therapeutics Competitors (1)

One of Sionna Therapeutics’s competitors is Stablix, a Venture Capital-Backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Stablix Venture Capital-Backed Boston, MA
You’re viewing 1 of 1 competitors. Get the full list »

Sionna Therapeutics Patents

Sionna Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026128667-A1 Nbd1 modulators and methods of using the same Pending 11-Dec-2024
AU-2025232488-A1 Methods of treating cftr-mediated diseases or disorders Pending 06-Mar-2024
WO-2025189008-A1 Methods of treating cftr-mediated diseases or disorders Pending 06-Mar-2024
WO-2025189008-A8 Methods of treating cftr-mediated diseases or disorders Pending 06-Mar-2024
AU-2024397852-A1 Compounds, compositions, and methods of using thereof Pending 15-Dec-2023 C07D513/18
To view Sionna Therapeutics’s complete patent history, request access »

Sionna Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sionna Therapeutics Investments (1)

Sionna Therapeutics’s most recent deal was a Corporate Asset Purchase with AbbVie (Rights of Cystic Fibrosis Therapies). The deal was made on 16-Jul-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
AbbVie (Rights of Cystic Fibrosis Therapies) 16-Jul-2024 Corporate Asset Purchase Buildings and Property
To view Sionna Therapeutics’s complete investments history, request access »

Sionna Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Sionna Therapeutics’s complete esg history, request access »

Sionna Therapeutics FAQs

  • When was Sionna Therapeutics founded?

    Sionna Therapeutics was founded in 2019.

  • Where is Sionna Therapeutics headquartered?

    Sionna Therapeutics is headquartered in Waltham, MA.

  • What is the size of Sionna Therapeutics?

    Sionna Therapeutics has 59 total employees.

  • What industry is Sionna Therapeutics in?

    Sionna Therapeutics’s primary industry is Drug Discovery.

  • Is Sionna Therapeutics a private or public company?

    Sionna Therapeutics is a Public company.

  • What is Sionna Therapeutics’s stock symbol?

    The ticker symbol for Sionna Therapeutics is SION.

  • What is the current stock price of Sionna Therapeutics?

    As of 19-Nov-2026 the stock price of Sionna Therapeutics is $2.97.

  • What is the current market cap of Sionna Therapeutics?

    The current market capitalization of Sionna Therapeutics is $134M.

  • Who are Sionna Therapeutics’s competitors?

    Stablix is a competitor of Sionna Therapeutics.

  • What is Sionna Therapeutics’s annual earnings per share (EPS)?

    Sionna Therapeutics’s EPS for 12 months was -$2.44.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process